Skip to main content

Advertisement

Table 2 Final main effects linear model of the association between baseline explanatory variables and day 3 lumefantrine concentration in ng/mL (456 patients).

From: Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

Variable Coefficient 95%CI p-value p-value (trend)
   lower upper   
female gender 791.4 125.2 1493.3 0.019  
unsupervised treatment -2538.2 -2995.0 -2046.8 <0.0001  
age      
   ≥15 years [reference]     0.358
   5–14 years 322.5 -657.8 1388.6 0.530  
   <5 years 462.3 -478.7 1480.2 0.345  
lumefantrine dose (mg/Kg)      
   ≥80 [reference]     0.033
   65–79 -463.2 -1336.2 488.2 0.329  
   50–64 -1009.2 -1892.5 -35.4 0.043  
   <50 -1237.2 -2386.6 79.5 0.064  
history of vomiting at inclusion -688.6 -1294.1 -44.8 0.036  
constant 5778.1 4313.1 7457.0   
    adjusted R2: 0.164
    p-value for goodness of fit: <0.0001